0 302

Cited 22 times in

Safety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use

DC FieldValueLanguage
dc.contributor.author최혜연-
dc.contributor.author허지회-
dc.contributor.author김영대-
dc.contributor.author남정모-
dc.contributor.author남효석-
dc.contributor.author양재훈-
dc.contributor.author이경열-
dc.contributor.author정요한-
dc.contributor.author조한진-
dc.date.accessioned2015-04-23T17:20:48Z-
dc.date.available2015-04-23T17:20:48Z-
dc.date.issued2010-
dc.identifier.issn0022-510X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/102287-
dc.description.abstractBACKGROUND: Hemorrhage is a major complication of thrombolytic treatment. Concerns have been raised about the risk of hemorrhage in patients having received warfarin. Therefore, different indications for thrombolytic treatment are in use for stroke patients on warfarin. However, it remains uncertain whether the prior warfarin use actually increases their risk of bleeding in patients treated with thrombolysis. METHODS: This study included 179 consecutive patients who had high-risk cardioembolic sources and received thrombolytic treatment. Patients were treated with intravenous thrombolytic agents, or underwent intraarterial thrombolysis if their international normalized ratio (INR) was ≤1.7. We compared the frequency of bleeding complications between patients with prior warfarin use and those without. We also investigated whether there were differences in functional outcome and recanalization rates between them. RESULTS: A prior warfarin use was present in 28 patients (15.6%). Although INR levels were higher in the prior warfarin group, the frequency of bleeding complications was not different between patients who received prior warfarin and those who did not. No differences were observed in patients with or without prior warfarin use, for successful recanalization rate (Thrombolysis in Myocardial Infarction grade 2 or 3), mortality, or modified Rankin score (≤2) at 3months. CONCLUSIONS: Thrombolytic therapy for patients who previously received warfarin and had an INR≤1.7 did not affect bleeding risk, clinical outcome, or recanalization rate. Our data suggest that patients with a history of prior warfarin use may be safely treated with thrombolytic agents when their INR levels are low.-
dc.description.statementOfResponsibilityopen-
dc.format.extent101~105-
dc.relation.isPartOfJournal of the Neurological Sciences-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleSafety and outcome after thrombolytic treatment in ischemic stroke patients with high-risk cardioembolic sources and prior subtherapeutic warfarin use-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Neurology (신경과학)-
dc.contributor.googleauthorYoung Dae Kim-
dc.contributor.googleauthorJung Hwan Lee-
dc.contributor.googleauthorYo Han Jung-
dc.contributor.googleauthorHye Yeon Choi-
dc.contributor.googleauthorChung Mo Nam-
dc.contributor.googleauthorJae Hoon Yang-
dc.contributor.googleauthorHan Jin Cho-
dc.contributor.googleauthorHyo Suk Nam-
dc.contributor.googleauthorKyung-Yul Lee-
dc.contributor.googleauthorJi Hoe Heo-
dc.identifier.doi10.1016/j.jns.2010.07.025-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA04217-
dc.contributor.localIdA04369-
dc.contributor.localIdA00702-
dc.contributor.localIdA01264-
dc.contributor.localIdA01273-
dc.contributor.localIdA02318-
dc.contributor.localIdA02648-
dc.contributor.localIdA03659-
dc.contributor.localIdA03922-
dc.relation.journalcodeJ01897-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0022510X10003485-
dc.contributor.alternativeNameChoi, Hye Yoen-
dc.contributor.alternativeNameHeo, Ji Hoe-
dc.contributor.alternativeNameKim, Young Dae-
dc.contributor.alternativeNameNam, Jung Mo-
dc.contributor.alternativeNameNam, Hyo Suk-
dc.contributor.alternativeNameYang, Jae Hoon-
dc.contributor.alternativeNameLee, Kyung Yul-
dc.contributor.alternativeNameJung, Yo Han-
dc.contributor.alternativeNameCho, Han Jin-
dc.contributor.affiliatedAuthorChoi, Hye Yoen-
dc.contributor.affiliatedAuthorHeo, Ji Hoe-
dc.contributor.affiliatedAuthorKim, Young Dae-
dc.contributor.affiliatedAuthorNam, Jung Mo-
dc.contributor.affiliatedAuthorNam, Hyo Suk-
dc.contributor.affiliatedAuthorYang, Jae Hoon-
dc.contributor.affiliatedAuthorLee, Kyung Yul-
dc.contributor.affiliatedAuthorJung, Yo Han-
dc.contributor.affiliatedAuthorCho, Han Jin-
dc.citation.volume298-
dc.citation.number1-2-
dc.citation.startPage101-
dc.citation.endPage105-
dc.identifier.bibliographicCitationJournal of the Neurological Sciences, Vol.298(1-2) : 101-105, 2010-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.